Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06499285 · ClinicalTrials.gov registry record · Phase 3
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
A Phase 3 study of Myelodysplastic Syndromes, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT06499285 is a Phase 3 study of Myelodysplastic Syndromes that is actively recruiting participants, run by Takeda. The registered enrollment target is 225 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06499285, a Phase 3 study of Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Elritercept
Study Locations (20)
California
- City of Hope - Duarte
- Los Angeles Cancer Network - Glendale
- UC San Diego Moores Cancer Center - La Jolla
Tennessee
- Tennessee Cancer Specialists - Knoxville
- Baptist Clinical Research Institute - Memphis
- Vanderbilt University Medical Center - Nashville
Texas
- Texas Oncology Northeast Texas - Denison
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine - Houston
- Texas Oncology Gulf Coast - The Woodlands
Florida
- University of Miami Hospital and Clinics - Miami
- Moffitt Cancer Center - Tampa
Maryland
- Johns Hopkins Hospital - Baltimore
- Maryland Oncology Hematolofy - Columbia
Ohio
- Gabrail Cancer Center Research - Canton
- Cleveland Clinic - Cleveland - Cleveland
Connecticut
- Smilow Cancer Hospital at Yale-New Haven - New Haven
Illinois
- ILCC. Illinois Cancer Centers - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2032-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06499285
The ClinicalTrials.gov registry entry for NCT06499285 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (21% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06499285 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT06499285 about?
NCT06499285 is a clinical study titled "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions". The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check...
What is the current status of trial NCT06499285?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2025-05-06. Estimated completion is 2032-05-01.
What conditions does trial NCT06499285 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT06499285?
The interventions under investigation include: Placebo (DRUG), Elritercept (DRUG).
Who is sponsoring clinical trial NCT06499285?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06499285 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
RECRUITING · Phase 3
-
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
ACTIVE NOT RECRUITING · Phase 3
-
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.